(S (NP (DT This) (NN paper)) (VP (VBZ deals) (PP (IN with) (NP (NP (DT the) (NN estimation)) (PP (IN of) (NP (NP (NP (NNS regions)) (PP (IN of) (NP (NN attraction)))) (PRN (-LRB- -LRB-) (NP (NNP RoAs)) (-RRB- -RRB-)))) (PP (IN under) (NP (JJ parametric) (NNS uncertainties))) (PP (IN for) (NP (NP (DT a) (NN cancer) (NN growth) (NN model)) (PP (IN with) (NP (JJ combined) (NNS therapies)))))))) (. .))
(S (NP (PRP We)) (VP (VBP propose) (NP (NP (DT a) (NN framework)) (PP (IN of) (NP (JJ probabilistic) (NN certification))) (, ,) (PP (VBN based) (PP (IN on) (NP (DT the) (VBN randomized) (NNS methods)))) (, ,)) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB derive) (NP (NP (ADJP (RB probabilistically) (JJ certified)) (NNP RoAs)) (PP (IN of) (NP (DT a) (NN cancer) (NN growth) (NN model))))))))) (. .))
(S (NP (NP (DT The) (NN model)) (SBAR (WHNP (IN that)) (S (NP (PRP we)) (VP (VBP consider) (PP (IN in) (NP (DT this) (NN paper))))))) (VP (VBZ describes) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NN tumor) (CC and) (NP (JJ immune) (NN system)))) (PP (IN in) (NP (NP (NN presence)) (PP (IN of) (NP (DT a) (JJ combined) (NN chemo-) (CC and) (NN immunotherapy))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBP model) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (DT the) (NN chemotherapy) (NN agent))) (PP (IN in) (NP (DT the) (NN body)))) (PP (IN via) (NP (DT a) (JJ pharmacokinetic) (NN equation)))) (. .))
